OSCE stationDrNB Cardiology – Viva master list

Clinical signs & syndromes viva list

79 signs · 395 viva questionsLast reviewed: October 2026
Merit MedScript seal

The bedside signs and OSCE photographs examiners show most often: pulses and JVP, skin, eye and nail signs, genetic and congenital syndromes, and the heart in systemic disease. Each entry tells you what to point at, the diagnosis, the clinical risk and the next step, followed by five examiner cross-examination questions.

How to present in the viva: Describe what you see before naming it (site, colour, shape, tenderness), name the sign, give the one or two conditions it points to, and finish with the bedside or investigation that confirms it.

APulse, JVP & bedside signs

1.Malar flush

  • What to point at: Plum-red or dusky discoloration over the cheeks.
  • Diagnosis: Mitral facies
  • Clinical risk: Severe mitral stenosis with low cardiac output and pulmonary hypertension.
  • Management: Echo for mitral valve area and PA pressure.
Viva questions (5)
  • Q: Pathophysiology?A: Low output with peripheral vasoconstriction and chronic hypoxaemia causing cutaneous venous stasis.
  • Q: How does it differ from the SLE rash?A: The SLE butterfly rash is an inflammatory dermatitis that spares the nasolabial folds.
  • Q: Classic valve disease?A: Rheumatic mitral stenosis.
  • Q: Extremities?A: Cool, with peripheral cyanosis.
  • Q: Reversible?A: Improves after relief of MS if output and PA pressure improve.

2.Peripheral cyanosis

  • What to point at: Blue fingers and toes with a pink tongue and lips.
  • Diagnosis: Peripheral cyanosis
  • Clinical risk: Low cardiac output, shock, cold exposure, arterial or venous obstruction.
  • Management: Treat the cause (restore output, warm, relieve obstruction).
Viva questions (5)
  • Q: Key difference from central cyanosis?A: The tongue and oral mucosa stay pink.
  • Q: Mechanism?A: Sluggish peripheral flow with increased oxygen extraction.
  • Q: Threshold for visible cyanosis?A: About 5 g/dL of deoxygenated haemoglobin in capillary blood.
  • Q: Anaemic patients?A: Cyanosis appears late or not at all; polycythaemic patients become cyanosed earlier.
  • Q: Does warming help?A: Yes, if due to cold-induced vasoconstriction — central cyanosis does not improve.

3.Quincke sign

  • What to point at: Visible capillary pulsation in the nail bed with gentle pressure on the nail tip.
  • Diagnosis: Severe chronic aortic regurgitation
  • Clinical risk: LV volume overload and heart failure.
  • Management: Echo for severity, LV size and function; surgical timing.
Viva questions (5)
  • Q: Cause of peripheral AR signs?A: Large stroke volume with rapid diastolic run-off — wide pulse pressure.
  • Q: Elsewhere?A: Lips pressed with a glass slide.
  • Q: Acute AR?A: Absent — pulse pressure is narrow.
  • Q: Quincke vs Corrigan?A: Quincke: capillary; Corrigan: visible forceful carotid pulsation.
  • Q: Diastolic BP?A: Very low.

4.Water-hammer (Corrigan) pulse

  • What to point at: Bounding pulse with rapid upstroke and collapse; visible carotid pulsation (Corrigan).
  • Diagnosis: Severe aortic regurgitation
  • Clinical risk: LV dilatation and dysfunction.
  • Management: Surgery if symptomatic, LVEF ≤50% or LVESD >50 mm (>25 mm/m²).
Viva questions (5)
  • Q: How to elicit at the radial?A: Raise the arm quickly while feeling the radial pulse with your palm.
  • Q: Traube sign?A: ‘Pistol-shot’ sound over the femoral artery.
  • Q: Duroziez sign?A: To-and-fro femoral murmur on partial compression with the stethoscope.
  • Q: Effect of tachycardia?A: Shorter diastole reduces regurgitant volume.
  • Q: Murmur?A: High-pitched early diastolic decrescendo murmur at the left sternal edge.

5.De Musset sign

  • What to point at: Head nodding in time with the heartbeat.
  • Diagnosis: Severe aortic regurgitation
  • Clinical risk: Marker of large stroke volume.
  • Management: Echo and surgical evaluation.
Viva questions (5)
  • Q: Named after?A: Alfred de Musset, French poet with aortic regurgitation.
  • Q: Mechanism?A: Ballistic force of a large stroke volume.
  • Q: Becker sign?A: Visible retinal artery pulsation (pupil pulsation is Landolfi sign).
  • Q: Müller sign?A: Systolic pulsation of the uvula.
  • Q: Reliable for LV function?A: No — they reflect wide pulse pressure only.

6.Kussmaul sign

  • What to point at: Rise (or failure to fall) of JVP on inspiration.
  • Diagnosis: Kussmaul sign
  • Clinical risk: Constrictive pericarditis, restrictive cardiomyopathy, RV infarction, severe TR.
  • Management: Echo, CT/CMR and catheterisation; pericardiectomy for constriction.
Viva questions (5)
  • Q: Normal response?A: JVP falls on inspiration.
  • Q: Mechanism?A: The right heart cannot accept increased venous return.
  • Q: Tamponade?A: Usually absent — tamponade has pulsus paradoxus instead.
  • Q: Y descent in constriction?A: Rapid and deep (Friedreich sign).
  • Q: Constriction vs restriction at catheter?A: Constriction shows ventricular interdependence (discordant RV/LV systolic pressures).

7.Large a wave in the JVP

  • What to point at: Prominent presystolic venous pulsation.
  • Diagnosis: Prominent a wave
  • Clinical risk: Tricuspid stenosis, pulmonary stenosis, pulmonary hypertension, RV hypertrophy.
  • Management: Treat the cause.
Viva questions (5)
  • Q: What is the a wave?A: Pressure rise from right atrial contraction.
  • Q: Why large?A: The RA contracts against an obstructed valve or stiff RV.
  • Q: Cannon a wave?A: RA contracting against a closed tricuspid valve.
  • Q: When?A: AV dissociation — complete heart block, VT (irregular); junctional rhythm (regular).
  • Q: When absent?A: Atrial fibrillation.

8.Large v (cv) wave in the JVP

  • What to point at: Large systolic venous wave obliterating the x descent (cv wave), with a rapid y descent.
  • Diagnosis: Severe tricuspid regurgitation
  • Clinical risk: Hepatic congestion, ascites, oedema.
  • Management: Diuretics; tricuspid repair or transcatheter therapy.
Viva questions (5)
  • Q: Normal v wave?A: RA filling while the tricuspid valve is closed.
  • Q: Why large?A: Regurgitant RV ejection into the RA.
  • Q: Abdominal sign?A: Pulsatile liver.
  • Q: Y descent?A: Rapid and deep.
  • Q: Carvallo sign?A: TR murmur louder on inspiration.

9.Differential cyanosis

  • What to point at: Cyanosis and clubbing of the toes with pink right hand (left hand variable).
  • Diagnosis: PDA with Eisenmenger physiology
  • Clinical risk: RV failure, paradoxical embolism.
  • Management: Targeted PAH therapy; closure contraindicated.
Viva questions (5)
  • Q: Why is the upper body pink?A: Arch vessels arise proximal to the duct.
  • Q: Why are the feet blue?A: Desaturated pulmonary blood shunts into the descending aorta.
  • Q: If you close the duct?A: Loss of the pop-off — acute RV failure.
  • Q: Left arm?A: May be partly cyanosed if the duct is near the left subclavian.
  • Q: Drugs?A: Endothelin receptor antagonists, PDE-5 inhibitors.

10.Abdominojugular reflux

  • What to point at: Sustained JVP rise ≥3 cm for ≥10–15 s during firm mid-abdominal pressure.
  • Diagnosis: Raised filling pressures
  • Clinical risk: Decompensated HF.
  • Management: Decongestion with loop diuretics.
Viva questions (5)
  • Q: Normal response?A: Transient rise that settles within a few beats.
  • Q: Positive test means?A: Raised right-sided pressure, often PCWP ≥15 mmHg.
  • Q: Breath-holding?A: Avoid — Valsalva gives a false positive; breathe normally.
  • Q: Right HF only?A: No — also reflects left-sided HF with raised filling pressures.
  • Q: Pressure applied?A: About 20–35 mmHg for 15–30 s.

11.Sydenham chorea

  • What to point at: Involuntary purposeless movements with emotional lability.
  • Diagnosis: Acute rheumatic fever (late)
  • Clinical risk: Rheumatic mitral disease.
  • Management: Penicillin prophylaxis; valproate or carbamazepine if severe.
Viva questions (5)
  • Q: Latent period?A: 1–8 months — longest of ARF features.
  • Q: Inflammatory markers?A: Often normal.
  • Q: Milkmaid grip?A: Rhythmic squeezing on gripping.
  • Q: During sleep?A: Disappears.
  • Q: Mechanism?A: Molecular mimicry against basal ganglia.

12.Pulsus paradoxus

  • What to point at: Inspiratory fall in systolic BP >10 mmHg on a manual cuff.
  • Diagnosis: Cardiac tamponade
  • Clinical risk: Obstructive shock.
  • Management: Urgent echo-guided pericardiocentesis.
Viva questions (5)
  • Q: Definition?A: Inspiratory SBP fall >10 mmHg.
  • Q: Misnomer?A: It exaggerates a normal response.
  • Q: Mechanism?A: Ventricular interdependence in a fixed pericardium.
  • Q: Without tamponade?A: Severe asthma, COPD, massive PE.
  • Q: Tamponade without paradoxus?A: ASD, severe AR, severe LV dysfunction, positive-pressure ventilation, regional tamponade.

13.Pulsus alternans

  • What to point at: Regular rhythm with alternating strong and weak pulses.
  • Diagnosis: Severe LV systolic dysfunction
  • Clinical risk: Advanced HF.
  • Management: GDMT; advanced HF evaluation.
Viva questions (5)
  • Q: Mechanism?A: Alternating calcium cycling and preload in a failing LV.
  • Q: Versus bigeminy?A: Alternans is regular; bigeminy is irregular.
  • Q: Enhance detection?A: Sitting or standing.
  • Q: BP cuff?A: Korotkoff sounds at half the rate just below systolic.
  • Q: Right HF?A: Almost always a sign of LV failure.

14.Pulsus parvus et tardus

  • What to point at: Small, slow-rising, late-peaking carotid pulse.
  • Diagnosis: Severe aortic stenosis
  • Clinical risk: Severe AS.
  • Management: Echo; TAVI or SAVR.
Viva questions (5)
  • Q: Why carotid?A: Central pulse reflects LV ejection.
  • Q: Elderly?A: Stiff arteries may mask it.
  • Q: Chest signs?A: Apical-carotid delay, thrill at the aortic area.
  • Q: S2?A: Soft, single or paradoxically split.
  • Q: Gallavardin phenomenon?A: Musical apical radiation mimicking MR.

15.Levine sign

  • What to point at: Clenched fist over the sternum describing pain.
  • Diagnosis: Ischaemic chest pain
  • Clinical risk: ACS.
  • Management: ECG within 10 minutes, troponin, aspirin.
Viva questions (5)
  • Q: Why a fist?A: Visceral pain is diffuse.
  • Q: Diagnostic?A: Supportive, not diagnostic.
  • Q: Atypical groups?A: Women, diabetics, elderly.
  • Q: Sharp pleuritic pain?A: Less likely ischaemic.
  • Q: Autonomic features?A: Sweating, nausea, angor animi.

16.Broadbent sign

  • What to point at: Systolic retraction of the left posterior lower intercostal spaces (11th–12th).
  • Diagnosis: Adherent (constrictive) pericarditis
  • Clinical risk: Right HF, low output.
  • Management: Imaging and catheterisation; pericardiectomy.
Viva questions (5)
  • Q: Mechanism?A: Pericardial adhesions to diaphragm and chest wall.
  • Q: In systole?A: The heart pulls the wall inward.
  • Q: Versus apical impulse?A: Inward rather than outward.
  • Q: Sensitivity?A: Low.
  • Q: Classic cause?A: Tuberculosis.

17.Pulsus bisferiens

  • What to point at: Two systolic peaks in the carotid or brachial pulse.
  • Diagnosis: AR (± AS); HOCM (spike and dome)
  • Clinical risk: Significant AR or obstructive HCM.
  • Management: Echo to define the cause.
Viva questions (5)
  • Q: Mechanism in AR?A: Percussion wave then tidal (reflected) wave from a large stroke volume.
  • Q: HOCM?A: Early rapid ejection, mid-systolic obstruction, then a second peak (spike-and-dome).
  • Q: Distinguish clinically?A: HOCM murmur louder with Valsalva; AR has a diastolic murmur.
  • Q: Best artery?A: Carotid or brachial.
  • Q: Nitrates in HOCM?A: Worsen obstruction.

18.Central cyanosis

  • What to point at: Blue tongue and lips with clubbing.
  • Diagnosis: Right-to-left shunt (e.g. Eisenmenger)
  • Clinical risk: Hypoxia, erythrocytosis, paradoxical embolism.
  • Management: Targeted PAH therapy; phlebotomy only for hyperviscosity symptoms; transplant.
Viva questions (5)
  • Q: Central vs peripheral?A: Arterial desaturation vs increased peripheral extraction.
  • Q: Response to 100% O₂?A: Minimal with a shunt.
  • Q: Threshold?A: ~5 g/dL deoxygenated haemoglobin.
  • Q: Why avoid routine phlebotomy?A: Iron deficiency and stroke risk.
  • Q: Fingers?A: Clubbing.

BSkin, eyes, nails & lipids

19.Splinter haemorrhages

  • What to point at: Thin linear dark-red or brown streaks running lengthwise under the nail; in endocarditis typically mid or proximal nail bed.
  • Diagnosis: Splinter haemorrhages
  • Clinical risk: Marker of possible infective endocarditis (systemic emboli, valve destruction, mycotic aneurysm).
  • Management: If endocarditis is suspected: three sets of blood cultures before antibiotics, TTE then TEE, empirical IV antibiotics if unwell.
Viva questions (5)
  • Q: Pathophysiology?A: Capillary haemorrhage from microemboli or vasculitis in the nail bed.
  • Q: Specific for endocarditis?A: No — trauma is the commonest cause (usually distal and few).
  • Q: Other causes?A: Vasculitis, antiphospholipid syndrome, psoriasis, trichinosis, high altitude.
  • Q: Painful?A: No (unlike Osler nodes).
  • Q: Location in endocarditis?A: Multiple, in the proximal or middle nail bed; traumatic splinters are distal.

20.Janeway lesions

  • What to point at: Painless, flat, erythematous or haemorrhagic macules on the palms and soles.
  • Diagnosis: Janeway lesions
  • Clinical risk: Acute infective endocarditis, especially S. aureus.
  • Management: Urgent blood cultures and echocardiography; empirical IV antibiotics.
Viva questions (5)
  • Q: Painful?A: No — painless.
  • Q: Pathology?A: Septic microemboli with dermal microabscesses.
  • Q: Classic organism?A: Staphylococcus aureus.
  • Q: Acute or subacute?A: Typically acute endocarditis.
  • Q: How do they differ from Osler nodes?A: Janeway: flat, painless, palms and soles. Osler: raised, painful, finger and toe pulps.

21.Osler nodes

  • What to point at: Tender, raised, purplish nodules on the pulps of the fingers or toes, lasting hours to days.
  • Diagnosis: Osler nodes
  • Clinical risk: Subacute infective endocarditis.
  • Management: Blood cultures and echocardiography; rheumatoid factor is one of the Duke immunological minor criteria.
Viva questions (5)
  • Q: Painful?A: Yes — tender.
  • Q: Pathology?A: Immune-complex vasculitis (microemboli may also contribute).
  • Q: Classic organism?A: Viridans streptococci.
  • Q: Do they contain bacteria?A: Usually sterile.
  • Q: Related lab marker?A: Rheumatoid factor — positive in about half of subacute endocarditis.

22.Clubbing

  • What to point at: Bulbous distal phalanges with loss of the nail-fold angle (Lovibond angle >180°) and loss of the Schamroth window.
  • Diagnosis: Digital clubbing
  • Clinical risk: Cyanotic congenital heart disease, endocarditis, lung cancer and chronic suppurative lung disease.
  • Management: Pulse oximetry (hands and feet), echo for right-to-left shunt, CXR for lung disease.
Viva questions (5)
  • Q: Mechanism?A: Megakaryocytes bypass the lung through shunts, lodge in digital capillaries and release PDGF and VEGF.
  • Q: Cyanotic causes?A: ToF, Eisenmenger syndrome, TGA, truncus, tricuspid atresia.
  • Q: Schamroth window?A: Diamond-shaped gap between opposed nails of the same fingers — lost in clubbing.
  • Q: Reversible?A: Yes, after correcting the cause.
  • Q: Differential clubbing?A: Toes (and sometimes left hand) clubbed and cyanosed but right fingers spared — PDA with Eisenmenger physiology.

23.Tendon xanthomas

  • What to point at: Nodular thickening of the Achilles tendons and extensor tendons of the hands.
  • Diagnosis: Familial hypercholesterolaemia
  • Clinical risk: Premature CAD.
  • Management: High-intensity statin + ezetimibe ± PCSK9 inhibitor; cascade family screening.
Viva questions (5)
  • Q: Genetic defect?A: LDL receptor, APOB or PCSK9 mutation.
  • Q: Painful?A: Usually not; occasionally tendinitis.
  • Q: Composition?A: Cholesterol-laden macrophages (foam cells).
  • Q: Regression?A: Slowly with intensive lipid lowering.
  • Q: Eruptive xanthomas?A: Small red-yellow papules from severe hypertriglyceridaemia, not high LDL.

24.Corneal arcus (juvenilis)

  • What to point at: Grey-white peripheral corneal ring with a clear zone near the limbus in a patient under about 45.
  • Diagnosis: Premature corneal arcus
  • Clinical risk: Marker of dyslipidaemia and premature CAD.
  • Management: Lipid profile and cardiovascular risk assessment.
Viva questions (5)
  • Q: In the elderly?A: Arcus senilis is common and largely benign.
  • Q: Composition?A: Lipid deposits in the corneal stroma.
  • Q: Vision?A: Not affected.
  • Q: Unilateral arcus?A: Suggests carotid stenosis on the side without the arcus.
  • Q: Reversible?A: No.

25.Frank sign

  • What to point at: Diagonal crease from the tragus across the earlobe.
  • Diagnosis: Diagonal earlobe crease
  • Clinical risk: Weak marker associated with CAD.
  • Management: Prompt for risk-factor assessment — not a diagnostic test.
Viva questions (5)
  • Q: Sensitivity or specificity?A: Neither is high; it is associated with CAD statistically.
  • Q: Proposed mechanism?A: Loss of dermal elastic fibres and microvascular disease.
  • Q: More predictive in?A: Younger patients.
  • Q: Immediate intervention?A: No.
  • Q: Bilateral?A: Associated with greater risk than unilateral.

26.Eruptive xanthomas

  • What to point at: Crops of small red-yellow papules on buttocks and extensor surfaces.
  • Diagnosis: Severe hypertriglyceridaemia
  • Clinical risk: Acute pancreatitis.
  • Management: Very-low-fat diet, fibrate, omega-3, glycaemic control, stop precipitants.
Viva questions (5)
  • Q: Triglyceride level?A: Usually >1,000 mg/dL.
  • Q: Permanent?A: No — resolve within weeks of lowering triglycerides.
  • Q: Pathology?A: Chylomicron-derived lipid taken up by dermal macrophages.
  • Q: Fundus?A: Lipaemia retinalis.
  • Q: Statin alone?A: Inadequate — fibrate and diet are first-line.

27.Xanthelasma

  • What to point at: Soft yellow plaques on the medial eyelids.
  • Diagnosis: Xanthelasma palpebrarum
  • Clinical risk: Independent marker of CAD and MI.
  • Management: Lipid profile and cardiovascular risk assessment.
Viva questions (5)
  • Q: Always hyperlipidaemia?A: No — about half have normal lipids.
  • Q: Composition?A: Cholesterol-laden foam cells in the dermis.
  • Q: Under 40?A: Look for FH.
  • Q: Regression with statins?A: Uncommon; excision or laser.
  • Q: Liver association?A: Primary biliary cholangitis.

28.Roth spots

  • What to point at: Retinal haemorrhages with pale centres.
  • Diagnosis: Infective endocarditis (immunological phenomenon)
  • Clinical risk: Marker of endocarditis.
  • Management: Blood cultures, echo, antibiotics.
Viva questions (5)
  • Q: Pale centre?A: Fibrin–platelet plug.
  • Q: Specific?A: No.
  • Q: Other causes?A: Leukaemia, severe anaemia, diabetic retinopathy, hypertension.
  • Q: Vision?A: Usually unaffected.
  • Q: Duke criterion?A: Minor (immunological phenomenon).

29.Hollenhorst plaque

  • What to point at: Bright refractile yellow crystal at a retinal arteriolar bifurcation.
  • Diagnosis: Cholesterol retinal embolus
  • Clinical risk: TIA, stroke, amaurosis fugax.
  • Management: Carotid imaging, antiplatelet, high-intensity statin.
Viva questions (5)
  • Q: Composition?A: Cholesterol.
  • Q: Source?A: Ipsilateral carotid or aortic arch atheroma.
  • Q: Symptom?A: Amaurosis fugax.
  • Q: Calcific emboli?A: White, non-refractile, from calcified valves.
  • Q: Infarction?A: Often transient — crystals may fragment and move on.

30.Livedo reticularis

  • What to point at: Lace-like purplish mottling of the legs that persists on warming.
  • Diagnosis: Cholesterol embolisation (or vasculitis)
  • Clinical risk: AKI, bowel ischaemia, digital necrosis.
  • Management: Supportive care, statin; avoid further arterial instrumentation; consider stopping anticoagulation.
Viva questions (5)
  • Q: Iatrogenic trigger?A: Catheterisation, aortic surgery, thrombolysis or anticoagulation.
  • Q: Lab clue?A: Eosinophilia, low complement, raised ESR.
  • Q: Mechanism?A: Obstructed dermal arterioles with venous plexus pooling.
  • Q: Warming?A: Physiological livedo fades; pathological does not.
  • Q: Why avoid anticoagulants?A: May impair plaque healing and cause further showers.

31.Blue toe syndrome

  • What to point at: Sudden painful blue or purple toes with palpable pedal pulses.
  • Diagnosis: Atheroembolic disease
  • Clinical risk: Necrosis, gangrene.
  • Management: Statin, antiplatelet, analgesia; avoid embolectomy.
Viva questions (5)
  • Q: Why are pulses palpable?A: Microemboli (~100–200 µm) block digital arterioles only.
  • Q: Classic triad?A: Skin signs, AKI, eosinophilia.
  • Q: Definitive test?A: Biopsy showing cholesterol clefts.
  • Q: Why clefts?A: Crystals dissolve during processing.
  • Q: Embolectomy?A: Not effective.

32.Pseudoxanthoma elasticum

  • What to point at: ‘Plucked chicken’ yellow papules on the neck and flexures.
  • Diagnosis: Pseudoxanthoma elasticum
  • Clinical risk: Premature CAD and PAD, GI bleeding.
  • Management: Risk-factor control; anti-VEGF for retinal neovascularisation.
Viva questions (5)
  • Q: Pathology?A: Calcification and fragmentation of elastic fibres.
  • Q: Fundus?A: Angioid streaks.
  • Q: Peripheral arteries?A: Early calcification and claudication.
  • Q: Myocardium?A: Rarely endocardial calcification and restriction.
  • Q: Inheritance?A: Autosomal recessive (ABCC6).

33.Hereditary haemorrhagic telangiectasia

  • What to point at: Multiple telangiectasias on lips, tongue, face and fingers; recurrent epistaxis.
  • Diagnosis: HHT (Osler–Weber–Rendu)
  • Clinical risk: Pulmonary AVMs, hepatic AVMs with high-output HF, anaemia.
  • Management: Screen for PAVMs; embolisation; iron replacement.
Viva questions (5)
  • Q: High-output HF?A: Mainly hepatic AVM shunting.
  • Q: PAVM presentation?A: Cyanosis, clubbing, paradoxical stroke or abscess.
  • Q: Response to 100% O₂?A: Incomplete — anatomical shunt.
  • Q: GI complication?A: Bleeding telangiectasias.
  • Q: Inheritance?A: Autosomal dominant (ENG, ACVRL1).

34.Erythema marginatum

  • What to point at: Pink rings with central clearing on trunk and proximal limbs, sparing the face.
  • Diagnosis: Acute rheumatic fever
  • Clinical risk: Rheumatic carditis.
  • Management: Penicillin, anti-inflammatory therapy, secondary prophylaxis.
Viva questions (5)
  • Q: Jones criterion?A: Major.
  • Q: Trigger?A: Heat makes it more visible.
  • Q: Scarring?A: None.
  • Q: Latent period?A: About 2–4 weeks after pharyngitis.
  • Q: After skin infection?A: Classically follows pharyngitis; skin infection may contribute in high-burden settings.

35.Subcutaneous nodules

  • What to point at: Firm painless nodules over extensor surfaces, scalp and spine.
  • Diagnosis: Acute rheumatic fever
  • Clinical risk: Strongly associated with carditis.
  • Management: Treat ARF; nodules resolve.
Viva questions (5)
  • Q: Jones criterion?A: Major.
  • Q: Painful?A: No.
  • Q: Histology?A: Fibrinoid necrosis with histiocytes, akin to Aschoff lesions.
  • Q: Duration?A: 1–4 weeks.
  • Q: Without carditis?A: Rare.

CGenetic & congenital syndromes

36.Arachnodactyly and thumb/wrist signs

  • What to point at: Long fingers; thumb sign (Steinberg) and wrist sign (Walker–Murdoch).
  • Diagnosis: Marfan syndrome
  • Clinical risk: Aortic root aneurysm and dissection, MVP.
  • Management: Beta-blocker or ARB, serial imaging, prophylactic root replacement.
Viva questions (5)
  • Q: Gene?A: FBN1 (fibrillin-1).
  • Q: Ocular sign?A: Ectopia lentis (upward).
  • Q: Surgery threshold?A: Root ≥50 mm, or ≥45 mm with risk factors.
  • Q: Commonest cause of death?A: Type A dissection.
  • Q: Loeys–Dietz difference?A: Bifid uvula, hypertelorism, arterial tortuosity, dissection at smaller sizes.

37.Webbed neck and shield chest

  • What to point at: Webbed neck, low posterior hairline, broad chest with widely spaced nipples, short stature.
  • Diagnosis: Turner syndrome (45,X)
  • Clinical risk: Bicuspid aortic valve, coarctation, aortic dissection.
  • Management: Lifelong cardiac imaging (CMR), BP control.
Viva questions (5)
  • Q: Commonest cardiac anomaly?A: Bicuspid aortic valve (~15–30%).
  • Q: Vascular anomaly?A: Coarctation (~10%).
  • Q: Before pregnancy?A: Aortic size index — pregnancy discouraged if ASI >2.5 cm/m² (or >2.0 with risk factors).
  • Q: Dissection without dilatation?A: Yes — risk is higher at any absolute size.
  • Q: Fertility?A: Usually primary ovarian failure.

38.Down syndrome facies

  • What to point at: Upslanting palpebral fissures, epicanthic folds, flat nasal bridge, protruding tongue, single palmar crease.
  • Diagnosis: Trisomy 21
  • Clinical risk: Atrioventricular septal defect; early pulmonary vascular disease.
  • Management: Neonatal echo for all; early repair.
Viva questions (5)
  • Q: Proportion with CHD?A: About 40–50%.
  • Q: Commonest defect?A: Complete AVSD.
  • Q: Why earlier Eisenmenger?A: Airway obstruction, hypoventilation and pulmonary vascular abnormalities.
  • Q: ECG in AVSD?A: Left (superior) axis deviation.
  • Q: VSD type?A: Inlet VSD.

39.Pectus excavatum

  • What to point at: Sunken sternum (funnel chest).
  • Diagnosis: Pectus excavatum (MVP, Marfan)
  • Clinical risk: RV compression (severe), MVP, aortic root dilatation in Marfan.
  • Management: Echo for MVP and aortic root; Nuss repair if significant.
Viva questions (5)
  • Q: Commonest valve lesion?A: MVP.
  • Q: ECG?A: Negative P in V1, incomplete RBBB, right axis from displacement.
  • Q: Echo?A: Poor windows and RV compression.
  • Q: Syndromes?A: Marfan, Loeys–Dietz, Ehlers–Danlos, Noonan.
  • Q: Severity?A: Haller index on CT >3.25.

40.Williams syndrome facies

  • What to point at: Elfin facies: broad forehead, periorbital fullness, short upturned nose, wide mouth.
  • Diagnosis: Williams–Beuren syndrome
  • Clinical risk: Supravalvar aortic stenosis, branch PA stenosis, sudden death (especially with anaesthesia).
  • Management: Surgical SVAS repair; calcium monitoring.
Viva questions (5)
  • Q: Deletion?A: 7q11.23.
  • Q: Gene for vascular disease?A: Elastin (ELN).
  • Q: SVAS on echo?A: Hour-glass narrowing above the sinotubular junction.
  • Q: Metabolic abnormality?A: Infantile hypercalcaemia.
  • Q: Coronary risk?A: Ostial obstruction and thickened coronaries.

41.Noonan syndrome

  • What to point at: Short stature, webbed neck, hypertelorism, ptosis, low-set ears, pectus.
  • Diagnosis: Noonan syndrome
  • Clinical risk: Dysplastic pulmonary stenosis, HCM.
  • Management: Balloon valvuloplasty (less effective) or surgery; HCM care.
Viva questions (5)
  • Q: Commonest defect?A: Pulmonary stenosis (~50–60%).
  • Q: Valve morphology?A: Thick dysplastic leaflets.
  • Q: Second commonest?A: HCM (~20%).
  • Q: Genetics?A: Autosomal dominant RASopathy — PTPN11 in ~50%.
  • Q: Karyotype?A: Normal (46,XX or 46,XY).

42.Holt–Oram syndrome

  • What to point at: Upper-limb radial ray defects (absent, hypoplastic or triphalangeal thumbs) with CHD.
  • Diagnosis: Heart–hand syndrome
  • Clinical risk: Atrial septal defect and conduction disease.
  • Management: Closure of defects; ECG/Holter for AV block.
Viva questions (5)
  • Q: Commonest defect?A: Secundum ASD.
  • Q: Laterality?A: Often asymmetric, worse on the left.
  • Q: Gene?A: TBX5 (autosomal dominant).
  • Q: Heart block?A: Yes, even without structural defects.
  • Q: Lower limbs?A: Not involved.

43.DiGeorge (22q11.2 deletion)

  • What to point at: Hooded eyelids, small mouth, bulbous nose tip, low-set ears, cleft palate.
  • Diagnosis: 22q11.2 deletion syndrome
  • Clinical risk: Conotruncal anomalies, hypocalcaemia, immunodeficiency.
  • Management: Surgical repair; calcium supplementation; irradiated blood products.
Viva questions (5)
  • Q: CATCH-22?A: Cardiac defects, Abnormal facies, Thymic hypoplasia, Cleft palate, Hypocalcaemia.
  • Q: Defect class?A: Conotruncal anomalies (truncus, ToF, interrupted arch) — strongly associated.
  • Q: Arch anomaly?A: Interrupted aortic arch type B.
  • Q: Why hypocalcaemia?A: Parathyroid hypoplasia.
  • Q: Irradiated blood?A: T-cell deficiency — risk of transfusion graft-versus-host disease.

44.Loeys–Dietz syndrome

  • What to point at: Bifid uvula or cleft palate, hypertelorism, arterial tortuosity, translucent skin.
  • Diagnosis: Loeys–Dietz syndrome
  • Clinical risk: Aggressive aneurysms and dissection at small sizes, throughout the arterial tree.
  • Management: Head-to-pelvis vascular imaging; early aortic surgery.
Viva questions (5)
  • Q: Genes?A: TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3.
  • Q: Compared with Marfan?A: Dissection occurs earlier and at smaller diameters.
  • Q: Surgery threshold?A: Root ≥45 mm, or ≥40 mm with high-risk features (ESC 2024).
  • Q: Aneurysms elsewhere?A: Yes — cerebral, visceral and peripheral.
  • Q: Skin?A: Translucent with visible veins and easy bruising.

45.Vascular Ehlers–Danlos syndrome

  • What to point at: Thin translucent skin, visible veins, thin lips and nose, easy bruising.
  • Diagnosis: Vascular EDS (type IV)
  • Clinical risk: Arterial, bowel and uterine rupture.
  • Management: BP control (celiprolol reduced events); avoid invasive procedures where possible.
Viva questions (5)
  • Q: Gene?A: COL3A1 (type III collagen).
  • Q: Joint hypermobility?A: Mainly small joints.
  • Q: Angiography?A: Avoid if possible — high risk of dissection or rupture.
  • Q: Non-cardiac sudden death?A: Spontaneous colonic rupture.
  • Q: Surgery?A: Tissues tear easily — very high risk.

46.Tuberous sclerosis skin lesions

  • What to point at: Facial angiofibromas, ash-leaf macules, shagreen patch, periungual fibromas.
  • Diagnosis: Tuberous sclerosis complex
  • Clinical risk: Cardiac rhabdomyomas — outflow obstruction, WPW, arrhythmia in infancy.
  • Management: Observation (regress); everolimus if obstructive.
Viva questions (5)
  • Q: Commonest paediatric cardiac tumour?A: Rhabdomyoma.
  • Q: Surgery?A: Rarely — they regress.
  • Q: Genes?A: TSC1 (hamartin) or TSC2 (tuberin).
  • Q: Location?A: Multiple, ventricular myocardium and septum.
  • Q: Ash-leaf spots?A: Seen better with a Wood's lamp.

47.Neonatal lupus

  • What to point at: Annular erythematous plaques on scalp and face of a neonate with bradycardia.
  • Diagnosis: Congenital complete heart block
  • Clinical risk: Complete heart block, cardiomyopathy, hydrops.
  • Management: Pacemaker for symptoms or low rates (<55 bpm, <70 with CHD); hydroxychloroquine in later pregnancies reduces recurrence.
Viva questions (5)
  • Q: Antibodies?A: Maternal anti-Ro/SSA (± anti-La/SSB).
  • Q: Mechanism?A: Inflammation and fibrosis of the fetal AV node.
  • Q: Mother symptomatic?A: Often not.
  • Q: Reversible block?A: Complete block is permanent.
  • Q: Rash?A: Fades by about 6 months.

48.Pectus carinatum

  • What to point at: Pigeon chest.
  • Diagnosis: Pectus carinatum (Marfan)
  • Clinical risk: Aortic root dilatation, MVP.
  • Management: Echo for aortic root.
Viva questions (5)
  • Q: Carinatum vs excavatum in Marfan?A: Carinatum scores 2 and excavatum 1 in the Ghent systemic score.
  • Q: Ghent nosology?A: Revised 2010 criteria: aortic root dilatation, ectopia lentis, FBN1 and systemic score.
  • Q: Enlarged root?A: Z-score ≥2.
  • Q: Lung restriction?A: Less than with excavatum.
  • Q: Drugs?A: Beta-blocker or losartan.

49.Neonatal lymphoedema

  • What to point at: Puffy hands and feet in a newborn girl.
  • Diagnosis: Turner syndrome
  • Clinical risk: Coarctation, bicuspid aortic valve.
  • Management: Four-limb BP and echo.
Viva questions (5)
  • Q: Cause?A: Lymphatic dysplasia.
  • Q: Cystic hygroma?A: Fetal neck lymphatic malformation — webbed neck later.
  • Q: Pulse sign?A: Radio-femoral delay.
  • Q: BP goal?A: Strict control.
  • Q: Echo in coarctation?A: High-velocity jet with a diastolic tail; catheter peak-to-peak gradient ≥20 mmHg is significant.

50.Pes cavus and kyphoscoliosis

  • What to point at: High-arched feet, hammer toes and scoliosis with ataxia.
  • Diagnosis: Friedreich ataxia
  • Clinical risk: Concentric hypertrophic cardiomyopathy, HF, arrhythmia.
  • Management: Echo and ECG surveillance; omaveloxolone for neurology.
Viva questions (5)
  • Q: Gene?A: GAA repeat in FXN (frataxin).
  • Q: Hypertrophy pattern?A: Usually concentric.
  • Q: LVOT obstruction?A: Uncommon.
  • Q: Commonest cause of death?A: Cardiac — HF or arrhythmia.
  • Q: Endocrine association?A: Diabetes mellitus.

51.Multiple lentigines (LEOPARD)

  • What to point at: Multiple dark lentigines over face, neck and trunk.
  • Diagnosis: Noonan syndrome with multiple lentigines
  • Clinical risk: HCM, pulmonary stenosis, conduction defects.
  • Management: Echo and ECG surveillance.
Viva questions (5)
  • Q: LEOPARD?A: Lentigines, ECG abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retardation of growth, Deafness.
  • Q: ECG?A: Conduction defects, prolonged PR, BBB.
  • Q: HCM?A: Often biventricular.
  • Q: Gene?A: PTPN11 (RASopathy).
  • Q: Sun exposure?A: Not related.

52.Blue sclerae

  • What to point at: Blue-grey sclerae from thin collagen.
  • Diagnosis: Osteogenesis imperfecta
  • Clinical risk: Aortic root dilatation, AR, MVP.
  • Management: Echo surveillance; bisphosphonates.
Viva questions (5)
  • Q: Defect?A: Type I collagen (COL1A1/COL1A2).
  • Q: Commonest cardiac lesion?A: Aortic regurgitation with root dilatation.
  • Q: Dissection?A: Rare.
  • Q: Peri-operative risk?A: Fragile bones and tissues.
  • Q: Other signs?A: Hearing loss, dentinogenesis imperfecta.

53.Progeria facies

  • What to point at: Large head, alopecia, prominent scalp veins, small jaw, aged skin in a child.
  • Diagnosis: Hutchinson–Gilford progeria
  • Clinical risk: Premature atherosclerosis, MI, stroke.
  • Management: Lonafarnib; aspirin; standard cardiovascular care.
Viva questions (5)
  • Q: Gene?A: LMNA (de novo).
  • Q: Abnormal protein?A: Progerin.
  • Q: Cholesterol?A: Usually normal.
  • Q: Arterial pathology?A: Vascular smooth-muscle loss, stiffening and calcification.
  • Q: Life expectancy?A: About 14–15 years, longer with lonafarnib.

54.Port-wine stain and limb hypertrophy

  • What to point at: Capillary malformation, varicosities and limb overgrowth.
  • Diagnosis: Klippel–Trenaunay syndrome
  • Clinical risk: DVT and PE.
  • Management: Compression, anticoagulation when indicated, sclerotherapy.
Viva questions (5)
  • Q: High-output HF?A: Mainly in Parkes Weber syndrome (high-flow AVMs); rare in KTS.
  • Q: Parkes Weber difference?A: Significant arteriovenous shunting.
  • Q: PE risk?A: Venous malformations promote thrombosis.
  • Q: Limb length?A: Longer and wider.
  • Q: AVM embolisation?A: For Parkes Weber high-flow lesions.

55.Congenital rubella syndrome

  • What to point at: Cataracts, sensorineural deafness, CHD.
  • Diagnosis: Congenital rubella
  • Clinical risk: PDA, branch pulmonary artery stenosis.
  • Management: PDA closure; branch PA angioplasty.
Viva questions (5)
  • Q: Commonest defect?A: PDA.
  • Q: Second?A: Peripheral PA stenosis.
  • Q: Vulnerable period?A: First trimester.
  • Q: Vaccine in pregnancy?A: Contraindicated (live).
  • Q: Peripheral PS murmur?A: Systolic or continuous, heard in the back and axillae.

56.Fetal alcohol syndrome

  • What to point at: Smooth philtrum, thin upper lip, short palpebral fissures, microcephaly.
  • Diagnosis: Fetal alcohol syndrome
  • Clinical risk: VSD, ASD.
  • Management: Echo screening; standard repair.
Viva questions (5)
  • Q: Commonest defect?A: VSD.
  • Q: Complex CHD?A: Uncommon.
  • Q: Mechanism?A: Disrupted neural crest migration.
  • Q: Safe alcohol dose?A: None.
  • Q: Non-cardiac feature?A: Neurodevelopmental disability.

57.Ellis–van Creveld syndrome

  • What to point at: Short-limbed dwarfism, postaxial polydactyly, dysplastic nails and teeth.
  • Diagnosis: Chondroectodermal dysplasia
  • Clinical risk: Common atrium.
  • Management: Surgical atrial septation.
Viva questions (5)
  • Q: Hallmark defect?A: Common (single) atrium.
  • Q: Inheritance?A: Autosomal recessive (EVC, EVC2).
  • Q: Population?A: Old Order Amish.
  • Q: VSD?A: Less common.
  • Q: Cyanosis?A: Mild, from mixing.

58.TAR syndrome

  • What to point at: Bilateral absent radii with thumbs present; thrombocytopenia.
  • Diagnosis: Thrombocytopenia–absent radius
  • Clinical risk: ToF, ASD.
  • Management: Platelet support; repair defects.
Viva questions (5)
  • Q: Differ from Holt–Oram?A: Thumbs present in TAR; abnormal or absent in Holt–Oram.
  • Q: CHD frequency?A: About 15–30%.
  • Q: Thrombocytopenia course?A: Improves after the first year.
  • Q: Bleeding triggers?A: Cow's milk intolerance, infections.
  • Q: Surgical challenge?A: Platelet management around bypass.

59.Rubinstein–Taybi syndrome

  • What to point at: Broad angulated thumbs and great toes, arched palate, intellectual disability.
  • Diagnosis: Rubinstein–Taybi syndrome
  • Clinical risk: PDA, VSD, ASD.
  • Management: Echo screening; standard repair.
Viva questions (5)
  • Q: Genes?A: CREBBP or EP300.
  • Q: CHD frequency?A: About one-third.
  • Q: Specific defect?A: No.
  • Q: Anaesthetic risk?A: Difficult airway.
  • Q: Digits?A: Radial deviation.

60.Alagille syndrome

  • What to point at: Cholestasis, butterfly vertebrae, triangular face with prominent forehead and pointed chin.
  • Diagnosis: Alagille syndrome
  • Clinical risk: Peripheral PA stenosis, ToF.
  • Management: Branch PA angioplasty or stenting; liver transplant if needed.
Viva questions (5)
  • Q: Classic lesion?A: Branch PA stenosis.
  • Q: Genes?A: JAG1 (NOTCH2).
  • Q: Eye finding?A: Posterior embryotoxon.
  • Q: Murmur?A: Systolic, radiating to back and axillae.
  • Q: Surgical risk?A: Liver disease, coagulopathy, malnutrition.

61.Carney complex

  • What to point at: Spotty pigmentation and blue naevi of face, lips and conjunctiva; endocrine overactivity.
  • Diagnosis: Carney complex
  • Clinical risk: Multiple recurrent cardiac myxomas.
  • Management: Resection; lifelong echo screening.
Viva questions (5)
  • Q: Myxoma difference?A: Younger, multiple, any chamber, recurrent.
  • Q: Gene?A: PRKAR1A (autosomal dominant).
  • Q: Endocrine?A: PPNAD (Cushing), pituitary adenoma.
  • Q: Testicular tumour?A: Large-cell calcifying Sertoli cell tumour.
  • Q: Screening?A: Annual echo from infancy.

62.Calf pseudohypertrophy

  • What to point at: Enlarged firm calves with Gowers sign.
  • Diagnosis: Duchenne muscular dystrophy
  • Clinical risk: Dilated cardiomyopathy in teens and twenties.
  • Management: ACE inhibitor from ~10 years, add MRA and beta-blocker; annual CMR/echo.
Viva questions (5)
  • Q: Why ‘pseudo’?A: Fat and fibrous replacement.
  • Q: Gene?A: Dystrophin (X-linked recessive).
  • Q: ECG?A: Tall R in V1, deep lateral Q waves.
  • Q: Cause?A: Posterobasal fibrosis.
  • Q: Becker?A: Milder skeletal disease but frequent cardiomyopathy.

63.Hatchet facies and frontal balding

  • What to point at: Long narrow face, temporal wasting, ptosis, frontal balding, myotonia.
  • Diagnosis: Myotonic dystrophy type 1
  • Clinical risk: Conduction disease, AV block, sudden death.
  • Management: Annual ECG/Holter; EPS-guided pacing (HV ≥70 ms); ICD in selected patients.
Viva questions (5)
  • Q: Gene?A: CTG repeat in DMPK.
  • Q: Myotonia?A: Delayed relaxation (e.g. handshake).
  • Q: Muscle severity vs cardiac risk?A: Poor correlation.
  • Q: Baseline ECG?A: First-degree AV block, QRS prolongation.
  • Q: Anaesthesia?A: Sensitivity to sedatives and depolarising relaxants.

64.Congenital deafness with long QT

  • What to point at: Profound bilateral sensorineural deafness in a child.
  • Diagnosis: Jervell and Lange-Nielsen syndrome
  • Clinical risk: Very long QT and sudden death.
  • Management: Propranolol or nadolol; ICD usually; avoid QT drugs.
Viva questions (5)
  • Q: Inheritance?A: Autosomal recessive (KCNQ1 or KCNE1).
  • Q: Romano–Ward?A: Autosomal dominant LQTS without deafness.
  • Q: Why deaf?A: IKs channels maintain endolymph.
  • Q: Triggers?A: Exercise and emotion (auditory triggers are typical of LQT2).
  • Q: Cochlear implant?A: Does not change cardiac risk.

DSystemic & endocrine disease

65.Periorbital purpura (‘raccoon eyes’)

  • What to point at: Periorbital purpura after minor trauma, coughing or Valsalva.
  • Diagnosis: AL amyloidosis
  • Clinical risk: Restrictive cardiomyopathy, arrhythmia, rapid HF.
  • Management: Free light chains and immunofixation, tissue biopsy; daratumumab-based chemotherapy.
Viva questions (5)
  • Q: Why purpura?A: Amyloid makes vessels fragile and binds factor X.
  • Q: ECG?A: Low voltage despite thick walls.
  • Q: In ATTR?A: Characteristic of AL.
  • Q: Catheter finding?A: Dip-and-plateau (square root) ventricular pressure.
  • Q: Drugs to use cautiously?A: Digoxin and non-dihydropyridine CCBs.

66.Macroglossia

  • What to point at: Large, firm tongue with lateral tooth indentations.
  • Diagnosis: AL amyloidosis
  • Clinical risk: Airway obstruction, restrictive HF.
  • Management: Biopsy (fat pad or tongue) with Congo red and typing.
Viva questions (5)
  • Q: Polarised light?A: Apple-green birefringence.
  • Q: ATTR?A: Rare — hallmark of AL.
  • Q: Atria?A: Biatrial enlargement, atrial standstill and thrombus.
  • Q: Echo texture?A: Granular ‘sparkling’ myocardium (non-specific).
  • Q: Why AL worse than ATTR?A: Light chains are directly cardiotoxic.

67.Carcinoid flushing

  • What to point at: Episodic red flushing of face and upper chest with diarrhoea and wheeze.
  • Diagnosis: Carcinoid heart disease
  • Clinical risk: Right-sided valve disease (TR, PS) and right HF.
  • Management: Somatostatin analogue; valve replacement in a specialist centre.
Viva questions (5)
  • Q: Mediator?A: Serotonin.
  • Q: Prerequisite for heart disease?A: Liver metastases.
  • Q: Why spared left heart?A: Lung inactivation (unless PFO or lung primary).
  • Q: Valve lesions?A: Thickened, retracted, fixed tricuspid and pulmonary leaflets.
  • Q: Urinary test?A: 24-h 5-HIAA.

68.Ankylosing spondylitis posture

  • What to point at: Question-mark posture with fixed kyphosis and loss of lumbar lordosis.
  • Diagnosis: Ankylosing spondylitis
  • Clinical risk: Aortitis, AR, AV block.
  • Management: Echo and ECG; valve surgery or pacing as needed.
Viva questions (5)
  • Q: Genetic marker?A: HLA-B27.
  • Q: AR mechanism?A: Aortic root inflammation with cusp retraction.
  • Q: Extent?A: Root and ascending aorta.
  • Q: Why AV block?A: Fibrosis extends into the basal septum.
  • Q: Spine X-ray?A: Bamboo spine.

69.Bronze skin pigmentation

  • What to point at: Slate-grey or bronze skin pigmentation with diabetes and liver disease.
  • Diagnosis: Haemochromatosis
  • Clinical risk: Cardiomyopathy (restrictive then dilated), arrhythmia.
  • Management: Venesection (hereditary) or chelation (transfusional); HF therapy.
Viva questions (5)
  • Q: Cardiac imaging?A: CMR T2*.
  • Q: Severe loading?A: T2* <10 ms.
  • Q: Conduction?A: AF, AV block and sinus node dysfunction.
  • Q: Reversible?A: Yes, if treated before fibrosis.
  • Q: Gene?A: HFE C282Y.

70.Sclerodactyly and telangiectasia

  • What to point at: Tight shiny finger skin, microstomia, facial telangiectasias.
  • Diagnosis: Systemic sclerosis (limited/CREST)
  • Clinical risk: PAH, myocardial fibrosis, pericardial effusion.
  • Management: Annual PAH screening (echo, DLCO, NT-proBNP; DETECT); RHC if suspected.
Viva questions (5)
  • Q: CREST?A: Calcinosis, Raynaud, oEsophageal dysmotility, Sclerodactyly, Telangiectasia.
  • Q: Leading cardiac death cause?A: PAH with RV failure.
  • Q: Myocardial disease?A: Patchy fibrosis, arrhythmia, diastolic dysfunction.
  • Q: Limited form antibody?A: Anti-centromere.
  • Q: Diffuse form antibody?A: Anti-Scl-70.

71.Malar (butterfly) rash

  • What to point at: Erythematous rash over cheeks and nose sparing the nasolabial folds.
  • Diagnosis: Systemic lupus erythematosus
  • Clinical risk: Pericarditis, Libman–Sacks endocarditis, premature CAD.
  • Management: Hydroxychloroquine, immunosuppression, echo screening.
Viva questions (5)
  • Q: Libman–Sacks?A: Sterile verrucous vegetations.
  • Q: Location?A: Mitral valve, either surface.
  • Q: Commonest cardiac manifestation?A: Pericarditis.
  • Q: Premature CAD?A: Inflammation, antiphospholipid antibodies and steroids.
  • Q: Neonatal heart block?A: Maternal anti-Ro.

72.Exophthalmos and goitre

  • What to point at: Proptosis, lid retraction, diffuse goitre with bruit.
  • Diagnosis: Graves disease
  • Clinical risk: AF, high-output HF.
  • Management: Beta-blocker, antithyroid drugs; anticoagulate AF by stroke risk.
Viva questions (5)
  • Q: High-output mechanism?A: Lower SVR and higher blood volume and heart rate.
  • Q: Direct cardiac effect?A: Upregulates α-myosin heavy chain and SERCA; increases β-receptor sensitivity.
  • Q: Cardioversion?A: Defer until euthyroid.
  • Q: Pulse pressure?A: Wide.
  • Q: Why propranolol?A: Rate control and reduced T4→T3 conversion at high doses.

73.Myxoedema facies

  • What to point at: Puffy face, periorbital oedema, coarse hair, loss of outer third of eyebrows.
  • Diagnosis: Severe hypothyroidism
  • Clinical risk: Pericardial effusion, bradycardia, accelerated atherosclerosis.
  • Management: Cautious levothyroxine; echo.
Viva questions (5)
  • Q: Tamponade?A: Rare — slow accumulation.
  • Q: ECG?A: Bradycardia, low voltage.
  • Q: SVR?A: Raised — diastolic hypertension.
  • Q: Why start slowly in cardiac patients?A: Risk of angina or MI.
  • Q: Lipids?A: Hypercholesterolaemia.

74.Acromegaly facies

  • What to point at: Prognathism, frontal bossing, macroglossia, spade-like hands.
  • Diagnosis: Acromegaly
  • Clinical risk: Concentric biventricular hypertrophy, hypertension, arrhythmia.
  • Management: Pituitary surgery, somatostatin analogues, BP control.
Viva questions (5)
  • Q: Cardiomyopathy cause?A: GH/IGF-1 effects plus hypertension.
  • Q: Echo?A: Concentric hypertrophy, diastolic dysfunction, later dilatation.
  • Q: Reversible?A: Partly, with cure.
  • Q: Arrhythmias?A: Ventricular ectopy, AF.
  • Q: Metabolic?A: Insulin resistance and diabetes.

75.Moon face and buffalo hump

  • What to point at: Round plethoric face, dorsocervical fat pad, central obesity, purple striae.
  • Diagnosis: Cushing syndrome
  • Clinical risk: Hypertension, premature CAD, HF.
  • Management: Treat the cause.
Viva questions (5)
  • Q: Hypertension mechanism?A: Mineralocorticoid receptor activation and vascular sensitisation.
  • Q: Electrolyte?A: Hypokalaemia (especially ectopic ACTH).
  • Q: Premature CAD?A: Insulin resistance, obesity, dyslipidaemia.
  • Q: Skin?A: Thin skin, bruising, wide purple striae.
  • Q: Risk after cure?A: Persists for years.

76.Arteriovenous fistula

  • What to point at: Dialysis or traumatic AV fistula with thrill and continuous bruit.
  • Diagnosis: High-output state
  • Clinical risk: High-output HF, LV dilatation.
  • Management: Banding or ligation if refractory HF.
Viva questions (5)
  • Q: Nicoladoni–Branham sign?A: Fistula compression slows the heart rate.
  • Q: Mechanism?A: Raised SVR triggers a baroreflex.
  • Q: High-output HF definition?A: HF with cardiac index >4 L/min/m² (output >8 L/min).
  • Q: Pulse?A: Bounding with wide pulse pressure.
  • Q: Recovery after closure?A: Often.

77.Argyll Robertson pupil

  • What to point at: Small irregular pupils that accommodate but do not react to light.
  • Diagnosis: Tertiary syphilis
  • Clinical risk: Syphilitic aortitis, root aneurysm, AR, coronary ostial stenosis.
  • Management: Penicillin; aortic surgery.
Viva questions (5)
  • Q: Aortic segment?A: Ascending aorta.
  • Q: Gross appearance?A: Tree-bark intima.
  • Q: Coronary ischaemia?A: Ostial stenosis.
  • Q: Dissection?A: Rare; saccular aneurysms.
  • Q: Murmur?A: Early diastolic AR murmur.

78.Erythema migrans

  • What to point at: Expanding annular erythema with central clearing after a tick bite.
  • Diagnosis: Lyme carditis
  • Clinical risk: Fluctuating high-grade AV block.
  • Management: IV ceftriaxone; temporary pacing if needed.
Viva questions (5)
  • Q: Permanent pacemaker?A: Rarely needed.
  • Q: Level of block?A: Usually AV node.
  • Q: Myocarditis?A: Mild and reversible.
  • Q: Vector?A: Ixodes ticks.
  • Q: Stage?A: Early disseminated.

79.Paget disease of bone

  • What to point at: Enlarged skull, frontal bossing, bowed tibiae in an elderly patient.
  • Diagnosis: High-output state with calcific valve disease
  • Clinical risk: High-output HF, calcific AS, conduction disease.
  • Management: Bisphosphonates; standard HF and valve care.
Viva questions (5)
  • Q: High-output mechanism?A: Hypervascular bone with AV shunting.
  • Q: Pulse pressure?A: Wide.
  • Q: Aortic stenosis?A: Accelerated calcification.
  • Q: Lab marker?A: Raised ALP with normal calcium.
  • Q: Oncological complication?A: Osteosarcoma.

Classes and cut-offs follow the ESC 2020–2024 and ACC/AHA guidelines current in October 2026; always apply your own institution's protocols.

meritmedscript.comDr. Sidhartha Mullapudi